Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LncRNA oncogene in liver cancer 1 (LOLI1)
- Target
- LOLI1
- Molecular classification
- Long non-coding RNA (lncRNA), Other
01
Overview
LncRNA oncogene in liver cancer 1 (LOLI1) is a long non-coding RNA (lncRNA) specifically identified for its oncogenic activity in liver cancer, particularly hepatocellular carcinoma (HCC)[1][4]. It is catalogued as ENSG00000241219 (RP11-572M11.1) and is characterized by low expression in normal tissue and elevated mutation rates in HCC[1]. Experimental data show that LOLI1 supports cell proliferation and viability in liver cancer cell lines: knockdown by antisense oligonucleotides reduces cancer cell growth, while CRISPR activation increases proliferation, confirming a direct role in tumor cell fitness[1]. There are currently no known drugs, clinical biomarkers, or specific safety concerns related to LOLI1, although its emerging role as a tumor driver suggests it is a candidate for future therapeutic targeting and as a biomarker in liver cancer research[1][4].
- Other names
- LncRNA Oncogene in Liver Cancer 1LOLI1ENSG00000241219RP11-572M11.1
02
Mechanism of action
Not established for drugs (experimental antisense oligonucleotides and CRISPR activation used for research)
03
Biological functions
Cell proliferationCell viabilityPotentially regulation of cytokine expression
04
Disease associations
CancerHepatocellular carcinoma (liver cancer)
Beyond the preview
Go deeper on LncRNA oncogene in liver cancer 1 (LOLI1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LncRNA oncogene in liver cancer 1 (LOLI1).